News | November 09, 2012

Use of Rosuvastatin Prior to Angioplasty Does Not Influence Troponin I Release Following Angioplasty

November 9, 2012 — A study found that the use of rosuvastatin prior to angioplasty did not influence the levels of troponin I, a sensitive indicator of muscle damage. Results were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Previous randomized studies have suggested that pretreatment with statins may reduce a periprocedural myocardial infarction (PMI) in patients with stable and/or unstable angina during an angioplasty or percutaneous coronary intervention (PCI). The purpose of this international, multicenter, randomized study was to investigate the effect of a one-day rosuvastatin loading therapy on troponin I (TnI) release in patients with stable or unstable angina undergoing PCI. Troponin is a protein that is released when the heart muscle has been damaged (for example, during a heart attack). The more damage there is to the heart, the greater the amount of troponin levels there will be in the blood.

Researchers assessed more than 1,700 patients for eligibility in the trial. Four hundred and seventy-eight patients with stable or unstable (troponin-negative) angina pectoris were enrolled and randomized in a 1:1 ratio. Patients in the experimental group were given 20 mg of rosuvastatin 12 hours prior to coronary angiography and 20 mg immediately prior to PCI (220 analyzable patients). Those in the control group underwent PCI without loading statin therapy (225 analyzable patients). In patients taking statins, rosuvastatin was added to their established statin therapy.

The serum concentration of troponin was measured at baseline, 6 to 12 hours after PCI, and 16 to 24 hours after PCI. The primary endpoint was the incidence of troponin l (Tnl) microleak defined as TnI elevation >1.5x upper limit of normal (ULN), and the secondary endpoint was the incidence of PMI defined as TnI elevation >3x ULN. The incidence of primary and secondary endpoint in the rosuvastatin vs. control group was 13.6% vs. 12.0% (p=0.61) and 8.2% vs. 7.1% (p=0.67), respectively.

While the incidence of the primary endpoint did not differ by inflammatory status as measured by c-reactive protein (CRP), in a secondary and exploratory analysis, patients with a c-reactive protein level ?2.0 mg/l had a decreased release of post-PCI TnI in the rosuvastatin group (0.032 ?g/l vs. 0.056 ?g/l; p = 0.045).

“One-day, high-dose rosuvastatin loading therapy did not reduce the occurrence of troponin microleak after angioplasty or periprocedural heart attack. However, these results suggest that, in patients with an advanced inflammatory status, rosuvastatin loading therapy might have a cardioprotective effect,” said lead researcher Josef Veselka, M.D., Ph.D, professor of medicine at Charles University and chief of the department of cardiology at University Hospital Motol in Prague, Czech Republic.

Veselka reported grant and research support from the Ministry of Health, Czech Republic.

For more information:

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init